You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hihg-risk MDS

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia, Myelodysplastic Tumor Trial (Magrolimab, 7+3, CPX-351)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Neoplasm
  • (no location specified)
Apr 24, 2023

MDS Trial (Roxadustat in combination with retinoic acid)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Roxadustat in combination with retinoic acid
  • (no location specified)
Aug 26, 2023

MDS, Myeloproliferative Tumor, Anemia Trial in Tampa (Luspatercept)

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
Feb 16, 2023

MDS Trial in Houston (Luspatercept)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Houston, Texas
    M D Anderson Cancer Center
Nov 2, 2023

Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML) Trial in Seoul

Active, not recruiting
  • Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)
  • Seoul, Korea, Republic of
    Asan Medical Center, University of Ulsan College of Medicine
Oct 19, 2023

Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)

Recruiting
  • Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
  • Ocala, Florida
  • +3 more
Jan 30, 2023

MDS/MPN Trial in Nanjing (Azacitidine (AZA) with Ruxolitinib)

Recruiting
  • MDS/MPN
  • Azacitidine (AZA) with Ruxolitinib
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital of Nanjing Medical University
Apr 17, 2023

Lower Risk MDS Per IPSS-R Trial (Luspatercept)

Not yet recruiting
  • Lower Risk MDS Per IPSS-R
  • (no location specified)
Jun 21, 2023

Lower-risk Myelodysplastic Syndrome Trial in Tampa (JSP191)

Recruiting
  • Lower-risk Myelodysplastic Syndrome
  • Tampa, Florida
    Moffitt Cancer Center
Jun 20, 2023

MDS Over Time - Comparison of Treated vs Untreated Patients

Completed
  • Myelodysplastic Syndromes
    • Vienna, Austria
      Hanusch Krankenhaus, 3.Medizinische Abteilung
    Nov 21, 2022

    Lower-risk MDS Patients

    Recruiting
    • MDS
      • Leipzig, Germany
        University Hospital Leipzig
      Oct 13, 2022

      MDS Trial in Seoul (cyclophosphamide, fludarabine, and antithymocyte globulin)

      Active, not recruiting
      • Myelodysplastic Syndromes
      • cyclophosphamide, fludarabine, and antithymocyte globulin
      • Seoul, Korea, Republic of
        Asan Medical Center, University of Ulsan College of Medicine
      Oct 19, 2023

      Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)

      Active, not recruiting
      • Acute Myelogenous Leukemia
      • Myelodysplastic Syndrome
      • Gemtuzumab Ozogamicin
      • Valhalla, New York
        New York Medical College
      Sep 26, 2022

      Low Risk MDS Trial (R906289 Monosodium (R289 Na))

      Not yet recruiting
      • Low Risk Myelodysplastic Syndromes
      • R906289 Monosodium (R289 Na)
      • (no location specified)
      Jul 22, 2022

      MDS Trial in Tampa (Canakinumab Injection, Darbepoetin Alfa)

      Recruiting
      • Myelodysplastic Syndromes
      • Canakinumab Injection
      • Darbepoetin Alfa
      • Tampa, Florida
        Moffitt Cancer Center
      Nov 21, 2022

      MDS, MDS, Thrombocytopenia Trial (Placebo, Romiplostim)

      Completed
      Has Results
      • MDS
      • +2 more
      • Placebo
      • Romiplostim
      • (no location specified)
      Nov 4, 2022

      MDS Trial in Hefei (Unrelated Umbilical Cord Blood, Venetoclax, Decetabine)

      Recruiting
      • Myelodysplastic Syndromes
      • Unrelated Umbilical Cord Blood
      • +3 more
      • Hefei, Anhui, China
        The First Affiliated Hospital of University of Science and Techn
      Oct 27, 2023

      MDS Trial (Yisui granule, Placebo)

      Not yet recruiting
      • MDS
      • Yisui granule
      • Placebo
      • (no location specified)
      Jan 13, 2023

      MDS Trial (Decitabine/Cedazuridine, Magrolimab)

      Not yet recruiting
      • Myelodysplastic Syndromes
      • (no location specified)
      Apr 18, 2023

      MDS Trial (Fasting-mimicking diet (FMD) and physiotherapy)

      Not yet recruiting
      • Myelodysplastic Syndromes
      • Fasting-mimicking diet (FMD) and physiotherapy
      • (no location specified)
      Jun 22, 2022

      MDS Trial (Hetrombopag)

      Not yet recruiting
      • Myelodysplastic Syndromes
      • (no location specified)
      May 23, 2022

      Myelodysplastic Syndrome (MDS) Trial in Worldwide (sabatolimab, azacitidine, venetoclax)

      Active, not recruiting
      • Myelodysplastic Syndrome (MDS)
      • Brasschaat, Belgium
      • +9 more
      Jan 19, 2023

      Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial in Worldwide (HDM201, MBG453, Venetoclax)

      Active, not recruiting
      • Acute Myeloid Leukemia (AML)
      • High-risk Myelodysplastic Syndrome (MDS)
      • Durham, North Carolina
      • +8 more
      Dec 13, 2022

      Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Baltimore (Azacitidine, Sargramostim)

      Completed
      Has Results
      • Acute Myeloid Leukemia
      • Myelodysplastic Syndrome
      • Baltimore, Maryland
        The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      Sep 23, 2022

      MDS Trial in United States (Lenalidomide, Luspatercept)

      Recruiting
      • Myelodysplastic Syndromes
      • Miami, Florida
      • +5 more
      Sep 28, 2022